HIV patients' gastrointestinal tolerability and treatment satisfaction after switching from lopinavir/ritonavir (LPV/r) SGC to co-formulated LPV/r tablets

Methods Adult patients under LPV/r SGC Tx for at least 6 months, and with >95% adherence, were included. Following data were collected: overall GI side-effects; presence and gradation of diarrhea according to WHO severity scale; antidiarrheal drugs administration during the last month under LPV/r SGC Tx, and during 2nd and 6th month after switching to LPV/r tablets. Also, patient Tx satisfaction grade and preferences data were gathered.